Loading....
The activities of the Let’s Talk Prostate Cancer (LTPC) Expert Group are funded by Astellas Pharma Inc., Amgen Inc and Pfizer Inc, which collectively contribute to and support the objectives of the Expert group.
Astellas Pharma Inc. have full and exclusive editorial control over the LTPC Website

INCIDENCE

In Hungary, the estimated incidence rate for prostate cancer is 133.2 per 100,000 population.1 With the European average of estimated prostate cancer incidence being 153.9 per 100,000, the incidence rate in Hungary is lower than the EU average.1

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-7$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed February 2022

Estimated prostate cancer incidence 2020
(crude rate per 100,000 population)

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed March 2022)

MORTALITY

In Hungary, the estimated mortality for prostate cancer is 31.6 per 100,000.1 Mortality in Hungary is therefore lower than the EU27 average of 32.1 per 100,000.1

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed February 2022)

Prostate cacner mortality 2020
(crude rate per 100,000 population)

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed March 2022)

SURVIVAL

There is no up-to-date data on the average five-year survival rates for prostate cancer in Hungary available, indicating the need for better outcome data collection for people affected by prostate cancer.

Prostate cacner age-standardised 5-year net survival (%)

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)

NATIONAL POLICES

In 2006, Hungary issued the National Cancer Control Programme. The increasing number of prostate cancers is mentioned as one of the causes for higher incidence of cancer within the male population in Hungary. Healthy diet is listed as a prevention method for prostate cancer. Hungarian authorities are currently developing a new cancer plan with the objective of improving patients’ survival and quality of life. In addition, a tax-benefit package has been introduced for patients suffering from prostate cancer.1

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 European Commission and OECD. State of Health in the EU – Hungary Country Health Profile 2019. Accessible at https://ec.europa.eu/health/sites/health/files/state/docs/2019_chp_hu_english.pdf (last accessed October 2023)

CLINICAL GUIDELINES

Hungary follows indications contained in the Guideline for the treatment of prostate cancer (2008). The recommended care pathway includes patient access to*:

Review by a multidisciplinary team
Support from a specialist nurse
Holistic needs assessment
A tailored treatment plan
Nutrition and exercise advice
Psychological support
Regular care reviews

Legend:

Recommendation included

Recommendation not included

*For a detailed explanation of the different patient support categories included in this scorecard, please follow the link.

CANCER CARE

Access to Specialists

There is approximately 1 urologist per 39,624 inhabitants in Hungary.1,2 Compared to the EU average, Hungary has fewer doctors (3.3 vs. 3.6 per 1 000 population). Workforce shortages have been exacerbated by an ageing health workforce and the emigration of many doctors (particularly specialists), which accelerated after the country’s accession to the EU in 2004.3

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 Boszormenyi-Nagy, G. Beszámoló az urológiai fekvőbeteg-ellátásról a 2018-as adatok alapján. Magyar Urologia. 2020. 26-27

2 United Nations, Population Division, Department of Economic and Social Affairs. World Population Prospects 2019. Accessible at https://population.un.org/wpp/Download/Files/1_Indicators%20(Standard)/
EXCEL_FILES/1_Population/WPP2019_POP_F01_1_TOTAL_POPULATION_BOTH_SEXES.xlsx
(last accessed March 2022)

3 European Commission and OECD. State of Health in the EU – Hungary Country Health Profile 2019. Accessible at https://read.oecd-ilibrary.org/social-issues-migration-health/hungary-country-health-profile-2019_4b7ba48c-en#page1   (last accessed March 2022)

Cost of cancer

In Hungary, the direct cost of cancer care and treatment per person is €63,1 which is considerably lower than the European average of €154 per person.2 In fact, Hungary spends much less on health than the EU average, both in absolute terms and as a share of GDP.3

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
2 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022) – average calculated from data included for individual countries.
3 European Commission and OECD. State of Health in the EU – Hungary Country Health Profile 2019. Accessible at https://ec.europa.eu/health/sites/health/files/state/docs/2019_chp_hu_english.pdf (last accessed March 2022)

Cancer medicines spend

€40 is spent on cancer medicines per capita in Hungary.1 Cancer medicines accounted for more than half of the direct costs in Hungary, in 2018, along with Croatia, Spain and Bulgaria.1 The question of access to medicines has gained attention in recent years. The government has taken action to engage in regional collaborations to improve equal access to medicines.2

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

1 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
2 European Commission and OECD. State of Health in the EU – Hungary Country Health Profile 2019. Accessible at https://ec.europa.eu/health/sites/health/files/state/docs/2019_chp_hu_english.pdf (last accessed March 2022)

Approximate number of inhabitats per urologist - 2018*

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

*Different data sources were used for Belgium, Hungary, Italy, Romania and the UK, which may use data from different years. See references below. No data was found for Cyprus, Luxembourg, Malta and Slovakia.

European Society of Residents in Urology (ESRU). Countries. March 2018. Accessible at https://esru.eu/?q=countries (last accessed March 2022)
Federal Public Service of Public Health, Safety of the Food Chain and the Environment. HWF STATAN 2019 (detailed statistics). 2019. Accessible at https://organesdeconcertation.sante.belgique.be/fr/documents/hwf-statan-2019-statistiques-detaillees (last accessed March 2022)
Boszormenyi-Nagy, G. Report on urological inpatient care based on 2018 data. Urologia Hungarica. Accessible at http://urologiahungarica.hu/index.php/2020/05/12/beszamolo-az-urologiai-fekvobeteg-ellatasrol-a-2018-as-adatok-alapjan/ (last accessed March 2022)
I.Stat. Personale sanitario. Accessible at http://dati.istat.it/Index.aspx?DataSetCode=DCIS_PERS_SANIT (last accessed March 2022)
Institutul National De Statistica. Activitatea Unitatilor Sanitare in Anul 2019. 2020. Accessible at https://insse.ro/cms/sites/default/files/field/publicatii/activitatea_unitatilor_sanitare_anul_2019.pdf (last accessed March 2022)
United Nations, Population Division, Department of Economic and Social Affairs. World Population Prospects 2019. Accessible at https://population.un.org/wpp/Download/Files/1_Indicators%20(Standard)/EXCEL_FILES/1_Population/
WPP2019_POP_F01_1_TOTAL_POPULATION_BOTH_SEXES.xlsx
(last accessed March 2022)
British Association of Urological Surgeons and The Specialist Advisory Committee in Urology. Workforce Report. 2018. Accessible at https://www.baus.org.uk/_userfiles/pages/files/publications/
Workforce_Report_Sep%202018%20ver%201.1.pdf
(last accessed March 2022)

Direct health cost of cancer per person - 2018 (€)

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)

Per capita cost of cancer medicines - 2018 (€)

Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members

Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)

ORGANISATIONS

Patient organisations

The main cancer patient organisation in Hungary is:

Hungarian League Against Cancer
https://www.rakliga.hu/

 

Reference Number: ONC_2020_0202_APE
Date of preparation: October 2020

Europe Digital Atlas